Podcast
Author(s):
In this episode, Stuart Weinzimer, MD sits down with hosts for a discussion on his research and experience with diabetes technology, the need to focus on patient-reported outcomes in pediatric diabetes, and strategies for meeting the practical needs of individuals with diabetes.
The role of pediatric endocrinologists is one requiring a practitioner to wear multiple hats. An example of this juggling of roles is Stuart Weinzimer, MD, professor and interim section chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine.
Throughout his career in pediatric endocrinology, Weinzimer has had to balance the roles of a pediatric endocrinologist, principal investigator of clinical trials, advocate for diabetes technology, and more. A member of the American Diabetes Association professional practice Committee, Weinzimer’s experience in real-world as well as research settings has left him uniquely equipped to provide perspective on optimal management of diabetes.
During this time at the 16th annual conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023), Weinzimer was chosen to present during the meeting’s marquee yearbook session. A session unique to the ATTD, the yearbook session lasts 90 minutes and features 15 leading experts providing 6-minute presentations of what they believe is the most important news within diabetes care and research from the preceding year. For his contribution to the session, Weinzimer provided perspectives on overcoming barriers and disparities in the real-world application of diabetes technology.
On the final day of the meeting, Weinzimer sat down to participate in a special edition episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives. In the episode, Weinzimer sits down with hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist and CGM program coordinator at the Cleveland Clinic, and Natalie Bellini, DNP, an endocrine nurse practitioner at R&B Medical Group, for a discussion on his research and experience with diabetes technology, the need to focus on patient-reported outcomes, and strategies for meeting the practical needs of individuals with diabetes.